HC Wainwright Reiterates Buy Rating for ReWalk Robotics (NASDAQ:LFWD)

ReWalk Robotics (NASDAQ:LFWD)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $13.00 price target on the stock.

ReWalk Robotics Stock Down 4.5 %

LFWD stock traded down $0.09 during trading on Wednesday, reaching $1.85. 8,625 shares of the stock were exchanged, compared to its average volume of 42,945. The firm’s 50 day moving average is $2.79 and its 200 day moving average is $3.69. ReWalk Robotics has a twelve month low of $1.85 and a twelve month high of $9.10.

ReWalk Robotics (NASDAQ:LFWD) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. ReWalk Robotics had a negative return on equity of 43.02% and a negative net margin of 77.21%. The business had revenue of $6.71 million for the quarter, compared to the consensus estimate of $6.71 million. During the same period in the prior year, the business earned ($0.35) EPS. On average, research analysts expect that ReWalk Robotics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of ReWalk Robotics

An institutional investor recently bought a new position in ReWalk Robotics stock. Kent Lake Capital LLC acquired a new position in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 157,361 shares of the company’s stock, valued at approximately $823,000. Kent Lake Capital LLC owned approximately 1.85% of ReWalk Robotics as of its most recent filing with the Securities and Exchange Commission. 26.76% of the stock is owned by institutional investors and hedge funds.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.